WASHINGTON, DC (May 16, 2019) — AAM President and CEO Chester "Chip" Davis, Jr. appeared on PBS Newshour last night to respond to allegations by Connecticut Attorney General William Tong, who was also a guest.
Generic medicines are 90 percent of all prescriptions filled and are available for 22 percent of total cost to the health care prescription drug dollar.
"That's an amazing value proposition that you can't see anywhere else in health care," Davis told host John Yang.
With the generics industry facing months of generic price deflation, Davis pointed out that the industry is “facing real sustainability challenges. They aren't focused on colluding with each other. They're trying to figure out a way that they can sustain their business operations, so that patients can continue to benefit from the drugs that they provide.”
As the case progresses, Davis stressed the importance of knowing the facts. “Trying a case in the court of public opinion that should be tried in the courts is not the way to ensure that patients have access to safe, affordable, and effective medicine,” he said.
He told Yang, “The members that I know and the people that work there get up every day with one mission in mind. They want to make sure that they can go and produce safe, high-quality, effective medicines at a price that patients can afford.”
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.